<DOC>
	<DOCNO>NCT00367757</DOCNO>
	<brief_summary>Patient Population : Patients AF symptomatic refractory least one antiarrhythmic medication . Patients must AF paroxysmal ( &gt; 4 episode within 6 month , two episode &gt; 6 hour within 1 year ) persistent ( sustained episode &lt; 6 month terminate cardioversion drug ) . Purpose : To compare trigger-based technique ( pulmonary vein isolation ) substrate-based technique ( high-frequency , fractionate EGMs ) combine approach AF ablation</brief_summary>
	<brief_title>STAR-AF : Substrate Versus Trigger Ablation Reduction Atrial Fibrillation Trial</brief_title>
	<detailed_description>Interventions : Patients randomize either wide circumferential pulmonary vein isolation ( `` trigger '' ) ablation high-frequency , fractionate electrograms AF ( `` substrate '' ) , hybrid approach combine trigger substrate . Both technique perform NavX map system standardized ablation catheter . Endpoint PVI isolation four PVs document circular catheter . Endpoint substrate-based ablation termination noninducibility AF . Up 2 procedure allow within 6 month . A 2 month blank period allow procedure early recurrence count . Outcomes : - Recurrence atrial fibrillation atrial tachycardia 3 , 6 , 12 month post-initial procedure . - Recurrence define symptom and/or ECG/Holter data show AF &gt; 2 min - Occurrence adverse event group post-procedure . - Quality life assessment 6 12 month post-initial procedure . Followup : - 3 , 6 , 12 month post-initial procedure . - Clinical data , ECG , Holter , loop recorder baseline visit . - QOL baseline , 3 , 6 12 month post-initial procedure .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Patients age 18 great . `` high burden '' paroxysmal atrial fibrillation persistent atrial fibrillation candidate AF ablation base AF symptomatic refractory least one antiarrhythmic medication . At least one episode AF must document ECG Holter within 12 month randomization trial . continuous anticoagulation warfarin ( INR 23 ) &gt; 4 week prior ablation . Patients must able willing provide write informed consent participate clinical trial . chronic atrial fibrillation . Patients AF felt secondary obvious reversible cause . inadequate anticoagulation define inclusion criterion . leave atrial thrombus spontaneous echo contrast TEE prior procedure . contraindication systemic anticoagulation heparin coumadin . previously undergone atrial fibrillation ablation . leave atrial size &gt; 55 mm . Patients may potentially pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>paroxysmal atrial fibrillation</keyword>
	<keyword>persistent atrial fibrillation</keyword>
	<keyword>high burden atrial fibrillation</keyword>
	<keyword>atrial fibrillation ablation</keyword>
	<keyword>Pulmonary vein isolation</keyword>
	<keyword>AF trigger</keyword>
	<keyword>complex fractionate electrograms</keyword>
	<keyword>CFE</keyword>
	<keyword>CFAE</keyword>
	<keyword>complex fractionate atrial electrograms</keyword>
	<keyword>refractory antiarrhythmic medication</keyword>
	<keyword>PVAI</keyword>
	<keyword>Ensite NavX</keyword>
	<keyword>NavX</keyword>
	<keyword>CoolPath catheter</keyword>
	<keyword>irrigate ablation catheter</keyword>
	<keyword>high burden paroxysmal persistent atrial fibrillation</keyword>
	<keyword>candidate AF ablation</keyword>
	<keyword>symptomatic AF</keyword>
	<keyword>AF refractory least one antiarrhythmic medication</keyword>
</DOC>